bevantolol
Sign in to saveAlso known as 1-(3,4-dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol, 1-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)-2-propanol, 1-[2-(3,4-dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol, 1-(3,4-dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol, (+-)-bevantolol
Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker. It was discovered and developed by Warner-Lambert but in January 1989 the company announced that it had withdrawn the New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?" it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.
Research
95 papers- Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions.Journal of clinical pharmacology · 1987
- Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.Drugs · 1988
- Bevantolol hydrochloride--preclinical pharmacologic profile.Angiology · 1986
- Pharmacology of bevantolol hydrochloride.The American journal of cardiology · 1986
- Bevantolol vs propranolol: a double-blind controlled trial in essential hypertension.Angiology · 1988
via PubMed
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker. It was discovered and developed by Warner-Lambert but in January 1989 the company announced that it had withdrawn the New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?" it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.
==References==
Excerpted from Wikipedia’s “bevantolol” article, available under the CC BY-SA 4.0 licence.